Prescription medicine costs to be capped in Spain as low-income residents face €8 monthly limit

Spain’s government has approved a reform of the pharmaceutical co-payment system that will reduce the amount many residents pay for prescription medicines, while introducing new monthly limits linked to income.

Under the changes, people on the lowest incomes will pay no more than €8.23 per month for state-funded medicines obtained through the public healthcare system. The reform also creates new payment bands for middle and higher earners and expands exemptions for vulnerable groups.

Reform aimed at lowering medicine costs

The measure forms part of a wider update to Spain’s pharmaceutical law and is intended to make access to medication more affordable, particularly for pensioners, low-income households and people with chronic illnesses who require regular prescriptions.

At present, patients in Spain contribute a percentage of the cost of prescription medicines depending on their income, employment status and whether they are pensioners. Although some pensioners already benefit from monthly caps, consumer groups and healthcare organisations have argued that the system has become uneven and does not adequately reflect rising living costs.

Lowest earners to receive monthly cap

The Ministry of Health said the revised structure would better protect people with lower incomes from spending large amounts on medicines each month. According to the government, households earning under €9,000 annually will face the lowest cap, meaning they will not spend more than €8.23 per month on prescription drugs covered by the national health system.

Several additional income brackets will also be introduced. While people on modest and middle incomes are expected to continue paying a proportion of medication costs, maximum monthly spending limits will apply in more cases than before. Higher earners will contribute more under the revised model.

Extra support for vulnerable groups

The reform also includes measures aimed at reducing financial pressure on vulnerable patients, including children with recognised disabilities and people receiving minimum income support payments. Some groups already exempt from pharmaceutical co-payments, such as certain long-term unemployed people and individuals with severe medical conditions, will continue to receive medicines without charge.

For residents living in Spain, the changes are likely to be most noticeable for those who regularly collect prescriptions through the public healthcare system. Pensioners and people managing chronic conditions such as diabetes, cardiovascular disease or respiratory illnesses often require several medications every month, meaning the introduction of lower caps could reduce household spending over the course of a year.

What the changes mean for foreign residents

The changes will apply to prescriptions issued through Spain’s state healthcare network rather than private medical insurance. Residents registered with the public health system and holding a valid health card will continue to receive medicines through pharmacies under the co-payment arrangement established by their income category.

For foreign residents living legally in Spain, including British nationals registered within the public healthcare system, the same rules apply as for Spanish citizens. The amount paid at the pharmacy counter depends on official income records and healthcare eligibility rather than nationality.

Questions over implementation and costs

Healthcare campaigners have broadly welcomed the proposal, arguing that some patients currently avoid collecting prescriptions because of cost. Studies carried out in Spain in recent years have shown that lower-income households are more likely to delay or reduce medication use for financial reasons, particularly among pensioners and unemployed people.

However, some regional governments and pharmacy organisations are expected to examine how the new system will be implemented in practice. Spain’s healthcare administration is partly decentralised, with regional authorities responsible for managing many public health services. Adjustments to payment systems and reimbursement procedures may therefore require coordination between the central government and autonomous communities.

Pressure on Spain’s healthcare budget

The reform is also expected to affect public spending on healthcare. Lower contributions from low-income patients mean the state will absorb a greater share of pharmaceutical costs. The government argues that the measure is justified because improving access to medicines can help prevent more serious health problems and reduce hospital admissions in the long term.

Spain has one of Europe’s largest public healthcare systems, with millions of prescriptions issued every year through local pharmacies. Rising demand linked to an ageing population has increased pressure on health budgets in recent years, particularly following periods of inflation that affected household costs and public expenditure alike.

The government has not yet confirmed the exact date on which the revised co-payment structure will fully enter into force, although the reform has now been formally approved and will move through the legislative process before implementation.